nach oben

World Journal of Urology

Erschienen in:

01.06.2012 | Topic paper

Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives

verfasst von: Nagalakshmi Nadiminty, Allen C. Gao

Erschienen in: World Journal of Urology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

The emergence of castration resistance has remained the primary obstacle in prostate cancer therapy for several decades. Mechanisms likely to be involved in castration-resistant progression have been studied extensively, but have failed to yield many meaningful and effective targets. The re-activation of the androgen receptor (AR) in castration-resistant prostate cancer (CRPC) is now recognized as the central event in this process, and therapeutic modalities are being devised to combat it.

Methods

A review of literature was performed to highlight the important factors that play a role in the aberrant activation of the AR in CRPC.

Results

Seminal and exciting advances made in the past few years in the discovery of the roles of new intrinsic factors such as intracrine androgens, gene fusions involving the ETS oncogenes, and splice variants of the AR are reviewed. New and emerging hypotheses about the involvement of factors such as cytokines and other signaling pathways are discussed.

Conclusions

This review summarizes the most recent advances in the persistent activation of the androgen receptor signaling pathway and provides a perspective about their significance in CRPC progression.

Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics. CA Cancer J Clin 60:277–300PubMedCrossRef

Cheng H, Snoek R, Ghaidi F, Cox ME, Rennie PS (2006) Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Res 66:10613–10620PubMedCrossRef

Visakorpi T, Hyytinen E, Koivisto P et al (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9:401–406PubMedCrossRef

Chen CD, Welsbie DS, Tran C et al (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33–39PubMedCrossRef

Palmberg C, Koivisto P, Kakkola L, Tammela TLJ, Kallioniemi OP, Visakorpi T (2000) Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 164:1992–1995PubMedCrossRef

Scher HI, Sawyers CL (2005) Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23:8253–8261PubMedCrossRef

Koochekpour S (2010) Androgen receptor signaling and mutations in prostate cancer. Asian J Androl 12:639–657PubMedCrossRef

Brooke GN, Bevan CL (2009) The role of androgen receptor mutations in prostate cancer progression. Curr Genomics 10:18–25PubMedCrossRef

Buchanan G, Yang M, Cheong A et al (2004) Structural and functional consequences of glutamine tract variation in the androgen receptor. Hum Mol Genet 13:1677–1692PubMedCrossRef

10.

Buchanan G, Yang M, Harris JM et al (2001) Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Mol Endocrinol 15:46–56PubMedCrossRef

11.

Taylor BS, Schultz N, Hieronymus H et al (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18:11–22PubMedCrossRef

12.

Jiang Y, Palma JF, Agus DB, Wang Y, Gross ME (2010) Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem 56:1492–1495PubMedCrossRef

13.

Steinkamp MP, O’Mahony OA, Brogley M et al (2009) Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade Therapy. Cancer Res 69:4434–4442PubMedCrossRef

14.

Tomlins SA, Bjartell A, Chinnaiyan AM et al (2009) ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol 56:275–286PubMedCrossRef

15.

Tomlins SA, Mehra R, Rhodes DR et al (2006) TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 66:3396–3400PubMedCrossRef

16.

Morris DS, Tomlins SA, Montie JE, Chinnaiyan AM (2008) The discovery and application of gene fusions in prostate cancer. BJU Int 102:276–282PubMedCrossRef

17.

Demichelis F, Fall K, Perner S et al (2007) TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26:4596–4599PubMedCrossRef

18.

Attard G, Swennenhuis JF, Olmos D et al (2009) Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 69:2912–2918PubMedCrossRef

19.

Klezovitch O, Risk M, Coleman I et al (2008) A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA 105:2105–2110PubMedCrossRef

20.

Bastus NC, Boyd LK, Mao X et al (2010) Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. Cancer Res 70:9544–9548PubMedCrossRef

21.

Fine SW, Gopalan A, Leversha MA et al (2010) TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. Mod Pathol 23:1325–1333PubMedCrossRef

22.

Yu J, Yu J, Mani R-S et al (2010) An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17:443–454PubMedCrossRef

23.

Carver BS, Tran J, Gopalan A et al (2009) Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 41:619–624PubMedCrossRef

24.

Yoshimoto M, Joshua AM, Cunha IW et al (2008) Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol 21:1451–1460PubMedCrossRef

25.

Salami SS, Schmidt F, Laxman B et al Combining urinary detection of TMPRSS2:ERG and CaP3 with serum PSA to predict diagnosis of prostate cancer. Urologic oncology: seminars and original investigations. (in press, corrected proof)

26.

Brenner JC, Ateeq B, Li Y et al (2011) Mechanistic rationale for inhibition of poly (ADP-Ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19:664–678PubMedCrossRef

27.

Wang Q, Carroll JS, Brown M (2005) Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell 19:631–642PubMedCrossRef

28.

Bulger M, Groudine M (1999) Looping versus linking: toward a model for long-distance gene activation. Genes Dev 13:2465–2477PubMedCrossRef

29.

Blackwood EM, Kadonaga JT (1998) Going the distance: the current view of enhancer action. Science 281:60–63PubMedCrossRef

30.

Wang Q, Li W, Liu XS et al (2007) A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 27:380–392PubMedCrossRef

31.

Wang Q, Li W, Zhang Y et al (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138:245–256PubMedCrossRef

32.

Hu R, Isaacs WB, Luo J (2011) A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate: n/a-n/a

33.

Tepper CG, Boucher DL, Ryan PE et al (2002) Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 62:6606–6614PubMed

34.

Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ (2008) Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68:5469–5477PubMedCrossRef

35.

Guo Z, Yang X, Sun F et al (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69:2305–2313PubMedCrossRef

36.

Hu R, Dunn TA, Wei S et al (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69:16–22PubMedCrossRef

37.

Watson PA, Chen YF, Balbas MD et al Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. In: Proceedings of the national academy of sciences 107:16759–16765

38.

Hornberg E, Ylitalo EB, Crnalic S et al (2011) Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One 6:e19059PubMedCrossRef

39.

Nishiyama T, Hashimoto Y, Takahashi K (2004) The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res 10:7121–7126PubMedCrossRef

40.

Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL (2005) Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11:4653–4657PubMedCrossRef

41.

Nakamura Y, Suzuki T, Nakabayashi M et al (2005) In situ androgen producing enzymes in human prostate cancer. Endocr Relat Cancer 12:101–107PubMedCrossRef

42.

Page ST, Lin DW, Mostaghel EA et al (2006) Persistent intraprostatic androgen concentrations after medical castration in healthy men. Clin Endocrinol Metab 91:3850–3856CrossRef

43.

Dillard PR, Lin M-F, Khan SA (2008) Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol 295:115–120PubMedCrossRef

44.

Mostaghel EA, Page ST, Lin DW et al (2007) Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 67:5033–5041PubMedCrossRef

45.

Leon CG, Locke JA, Adomat HH et al (2010) Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate 70:390–400PubMed

46.

Pfeiffer MJ, Smit FP, Sedelaar JP, Schalken JA (2011) Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer. Mol Med. doi:10.2119/molmed.2010.00143

47.

Mostaghel EA, Nelson PS (2008) Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab 22:243–258PubMedCrossRef

48.

Hofland J, van Weerden WM, Dits NFJ et al (1999) Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res 70:1256–1264CrossRef

49.

Mostaghel EA, Montgomery B, Nelson PS (2009) Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease. Urol Oncol Semin Orig Investig 27:251–257CrossRef

50.

George DJ, Halabi S, Shepard TF et al (2005) The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res 11:1815–1820PubMedCrossRef

51.

Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM (2001) Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 58:1008–1015PubMedCrossRef

52.

Corcoran NM, Costello AJ (2003) Interleukin-6: minor player or starring role in the development of hormone-refractory prostate cancer? BJU Int 91:545–553PubMedCrossRef

53.

Lee SO, Chun JY, Nadiminty N, Lou W, Gao AC (2007) Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate 67:764–773PubMedCrossRef

54.

Feng S, Tang Q, Sun M, Chun JY, Evans CP, Gao AC (2009) Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. Mol Cancer Ther 8:665–671PubMedCrossRef

55.

Ueda T, Mawji NR, Bruchovsky N, Sadar MD (2002) Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Chem Biol 277:38087–38094CrossRef

56.

Chun JY, Nadiminty N, Dutt S et al (2009) Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res 15:4815–4822PubMedCrossRef

57.

Culig Z Cytokine disbalance in common human cancers. Biochimica et Biophysica Acta (BBA). Mole Cell Res 1813:308–314

58.

Santer FdrR, Malinowska K, Culig Z, Cavarretta IT (2010) Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocr Relat Cancer 17:241–253

59.

Taguchi Y, Yamamoto M, Yamate T et al (1998) Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage. Proc Assoc Am Physicians 110:559–574

60.

García-Moreno C, Méndez-Dávila C, de la Piedra C, Castro-Errecaborde NA, Traba ML (2002) Human prostatic carcinoma cells produce an increase in the synthesis of interleukin-6 by human osteoblasts. Prostate 50:241–246PubMedCrossRef

61.

Smith PC, Keller ET (2001) Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate 48:47–53CrossRef

62.

Wallner L, Dai J, Escara-Wilke J et al (2006) Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res 66:3087–3095PubMedCrossRef

63.

Dorff TB, Goldman B, Pinski JK et al (2010) Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (Siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res 16:3028–3034

64.

Karkera J, Steiner H, Li W et al (2011) The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate (Epub ahead of print)

65.

Takeshi U, Sadar MD, Suzuki H et al (2005) Interleukin-4 in patients with prostate cancer. Anticancer Res 25:4595–4598PubMed

66.

Lee SO, Lou W, Hou M, Onate SA, Gao AC (2003) Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway. Oncogene 22:7981–7988PubMedCrossRef

67.

Lee SO, Chun JY, Nadiminty N, Lou W, Feng S, Gao AC (2009) Interleukin-4 activates androgen receptor through CBP/p300. Prostate 69:126–132PubMedCrossRef

68.

Lee SO, Lou W, Nadiminty N, Lin X, Gao AC (2005) Requirement for NF-κB in interleukin-4-induced androgen receptor activation in prostate cancer cells. Prostate 64:160–167PubMedCrossRef

69.

Lee SO, Pinder E, Chun JY, Lou W, Sun M, Gao AC (2008) Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells. Prostate 68:85–91PubMedCrossRef

70.

Huang J, Yao JL, Zhang L et al (2005) Differential expression of interleukin-8 and Its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate can./cer. Am J Pathol 166:1807–1815PubMedCrossRef

71.

Veltri RW, Miller MC, Zhao G et al (1999) Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology 53:139–147PubMedCrossRef

72.

Seaton A, Scullin P, Maxwell PJ et al (2008) Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis 29:1148–1156PubMedCrossRef

73.

Lee L-F, Louie MC, Desai SJ et al (2004) Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene 23:2197–2205PubMedCrossRef

74.

Waugh DJJ, Wilson C (2008) The interleukin-8 pathway in cancer. Clin Cancer Res 14:6735–6741PubMedCrossRef

75.

MacManus CF, Pettigrew J, Seaton A et al (2007) Interleukin-8 signaling promotes translational regulation of cyclin D in androgen-independent prostate cancer cells. Mol Cancer Res 5:737–748PubMedCrossRef

76.

Wilson C, Wilson T, Johnston PG, Longley DB, Waugh DJJ (2008) Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. Mol Cancer Ther 7:2649–2661PubMedCrossRef

77.

Wilson C, Purcell C, Seaton A et al (2008) Chemotherapy-induced CXC-Chemokine/CXC-Chemokine receptor signaling in Metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-ÎºB transcription and evasion of apoptosis. J Pharmacol Exp Ther 327:746–759PubMedCrossRef

78.

Singh R, Lokeshwar B (2009) Depletion of intrinsic expression of Interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs. Mol Cancer 8:57PubMedCrossRef

79.

Dhir R, Ni Z, Lou W, DeMiguel F, Grandis JR, Gao AC (2002) Stat3 activation in prostatic carcinomas. Prostate 51:241–246PubMedCrossRef

80.

Ok Lee S, Lou W, Qureshi KM, Mehraein-Ghomi F, Trump DL, Gao AC (2004) RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. Prostate 60:303–309CrossRef

81.

Matsuda T, Junicho A, Yamamoto T et al (2001) Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells. Biochem Biophys Res Commun 283:179–187PubMedCrossRef

82.

De Miguel F, Lee S, Onate S, Gao A (2003) Stat3 enhances transactivation of steroid hormone receptors. Nucl Recept 1:3PubMedCrossRef

83.

De Miguel F, Lee SO, Lou W et al (2002) Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice. Prostate 52:123–129CrossRef

84.

Huang H, Murphy T, Shu P, Barton A, Barton B (2005) Stable expression of constitutively-activated STAT3 in benign prostatic epithelial cells changes their phenotype to that resembling malignant cells. Mol Cancer 4:2PubMedCrossRef

85.

Ammirante M, Luo J-L, Grivennikov S, Nedospasov S, Karin M (2010) B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464:302–305PubMedCrossRef

86.

Palvimo JJ, Reinikainen P, Ikonen T, Kallio PJ, Moilanen A, Jänne OA (1996) Mutual transcriptional interference between RelA and androgen receptor. J Biol Chem 271:24151–24156PubMedCrossRef

87.

Cinar B, Yeung F, Konaka H et al (2004) Identification of a negative regulatory cis-element in the enhancer core region of the prostate-specific antigen promoter: implications for intersection of androgen receptor and nuclear factor-kappaB signalling in prostate cancer cells. Biochem J 379:421–431PubMedCrossRef

88.

Zhang L, Altuwaijri S, Deng F et al (2009) NF-[kappa]B regulates androgen receptor expression and prostate cancer growth. Am J Pathol 175:489–499PubMedCrossRef

89.

Jin RJ, Lho Y, Connelly L et al (2008) The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res 68:6762–6769PubMedCrossRef

90.

Ishiguro H, Akimoto K, Nagashima Y et al (2009) aPKCε promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6. Proc Natl Acad Sci 106:16369–16374PubMedCrossRef

91.

Rajasekhar VK, Studer L, Gerald W, Socci ND, Scher HI (2011) Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-[kappa]B signalling. Nat Commun 2:162PubMedCrossRef

92.

Wang J, Cai Y, Shao L-j et al (2010) Activation of NF-ÎºB by TMPRSS2/ERG fusion isoforms through toll-like receptor-4. Cancer Res 71:1325–1333PubMedCrossRef

93.

Lessard L, Begin LR, Gleave ME, Mes-Masson AM, Saad F (2005) Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer 93:1019–1023PubMedCrossRef

94.

Nadiminty N, Chun JY, Lou W, Lin X, Gao AC (2008) NF-κB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen-deprivation. Prostate 68:1725–1733PubMedCrossRef

95.

Lessard L, Saad F, Le Page C et al (2007) NF-[kappa]B2 processing and p52 nuclear accumulation after androgenic stimulation of LNCaP prostate cancer cells. Cell Signal 19:1093–1100PubMedCrossRef

96.

Nadiminty N, Lou W, Sun M et al (2010) Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. Cancer Res 70:3309–3319PubMedCrossRef

97.

Nadiminty N, Dutt S, Tepper C, Gao AC (2010) Microarray analysis reveals potential target genes of NF-κB2/p52 in LNCaP prostate cancer cells. prostate 70:276–287PubMed

98.

Nadiminty N, Chun JY, Hu Y, Dutt S, Lin X, Gao AC (2007) LIGHT, a member of the TNF superfamily, activates Stat3 mediated by NIK pathway. Biochem Biophys Res Commun 359:379–384PubMedCrossRef

99.

Nadiminty N, Lou W, Lee SO, Lin X, Trump DL, Gao AC (2006) Stat3 activation of NF-ÎºB p100 processing involves CBP/p300-mediated acetylation. Proc Natl Acad Sci 103:7264–7269PubMedCrossRef

Titel: Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives
verfasst von: Nagalakshmi Nadiminty
Allen C. Gao
Publikationsdatum: 01.06.2012
Verlag: Springer-Verlag
Erschienen in: World Journal of Urology / Ausgabe 3/2012
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-011-0771-3

Neu im Fachgebiet Urologie

Patrone im Penis bringt Urologen in Gefahr

30.05.2024 Operationen am Penis Nachrichten

In Lebensgefahr brachte ein junger Mann nicht nur sich selbst, sondern auch das urologische Team, das ihm zu Hilfe kam: Er hatte sich zur Selbstbefriedigung eine scharfe Patrone in die Harnröhre gesteckt.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives

Abstract

Background

Methods

Results

Conclusions

Neu im Fachgebiet Urologie

Patrone im Penis bringt Urologen in Gefahr

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Fehlerkultur in der Medizin – Offenheit zählt!

Update Urologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

Value of enhanced transrectal ultrasound targeted biopsy for prostate cancer diagnosis: a retrospective data analysis

Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment

Akt signalling parameters are different in oncocytomas compared to renal cell carcinoma

Advances in small molecule inhibitors of androgen receptor for the treatment of advanced prostate cancer

Urinary urgency: a review of its assessment as the key symptom of the overactive bladder syndrome

NF-κB signaling in prostate cancer: A promising therapeutic target?

Neu im Fachgebiet Urologie

Patrone im Penis bringt Urologen in Gefahr

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Fehlerkultur in der Medizin – Offenheit zählt!

Update Urologie